Allogene Therapeutics Inc
ALLO1.145USD
+0.065+6.02%
交易中 （美東）報價延遲15分鐘
250.30M總市值
虧損本益比TTM
關於 Allogene Therapeutics Inc 公司
Allogene Therapeutics, Inc. 是一家臨牀階段的免疫腫瘤學公司。該公司專注於開發用於治療癌症和自身免疫性疾病的基因工程同種異體 T 細胞候選產品。該公司專注於四個核心項目：大 B 細胞淋巴瘤 (LBCL)、慢性淋巴細胞白血病 (CLL)、自身免疫性疾病和腎細胞癌。該公司正在利用蛋白質工程、基因編輯、基因插入和先進的專有 T 細胞製造技術開發多種同種異體嵌合抗原受體 (CAR) T 細胞候選產品。其候選產品 cemacabtagene ansegedleucel（簡稱 cema-cel）是一種工程同種異體 CAR T 細胞候選產品，靶向 CD19，CD19 是一種在 B 細胞細胞表面表達的蛋白質，也是 B 細胞驅動的血液系統惡性腫瘤的經過驗證的靶標。該公司專注於開發用於 LBCL 和 CLL 的 cema-cel。其產品線還包括 ALLO-316、ALLO-329 和 ALLO-647。
公司簡介
公司代碼ALLO
公司名稱Allogene Therapeutics Inc
上市日期Oct 11, 2018
CEODr. David D Chang, M.D., Ph.D.
員工數量226
證券類型Ordinary Share
年結日Oct 11
公司地址210 East Grand Avenue
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94080
電話16504572700
網址https://allogene.com/
公司代碼ALLO
上市日期Oct 11, 2018
CEODr. David D Chang, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.56M
-3.60%
Dr. David D Chang, M.D., Ph.D.
Dr. David D Chang, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.72M
-7.46%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
478.17K
-0.90%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
303.06K
--
Mr. Owen N. Witte, M.D.
Mr. Owen N. Witte, M.D.
Independent Director
Independent Director
292.83K
+14.59%
Mr. Benjamin Machinas (Ben) Beneski
Mr. Benjamin Machinas (Ben) Beneski
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
218.51K
--
Mr. Earl Martin Douglas, Esq.
Mr. Earl Martin Douglas, Esq.
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
110.21K
-5.49%
Dr. Zachary Roberts, M.D., Ph.D.
Dr. Zachary Roberts, M.D., Ph.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
101.90K
-38.68%
Ms. Deborah M. (Debbie) Messemer
Ms. Deborah M. (Debbie) Messemer
Independent Director
Independent Director
45.96K
-44.53%
Mr. Todd B. Sisitsky
Mr. Todd B. Sisitsky
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.56M
-3.60%
Dr. David D Chang, M.D., Ph.D.
Dr. David D Chang, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.72M
-7.46%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
478.17K
-0.90%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
303.06K
--
Mr. Owen N. Witte, M.D.
Mr. Owen N. Witte, M.D.
Independent Director
Independent Director
292.83K
+14.59%
Mr. Benjamin Machinas (Ben) Beneski
Mr. Benjamin Machinas (Ben) Beneski
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
218.51K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月3日 週日
更新時間: 8月3日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Pfizer Inc
10.07%
TPG Capital, L.P.
8.56%
Citadel Advisors LLC
6.10%
Capital World Investors
5.61%
Lynx1 Capital Advisors LLC
5.06%
Other
64.61%
持股股東
持股股東
佔比
Pfizer Inc
10.07%
TPG Capital, L.P.
8.56%
Citadel Advisors LLC
6.10%
Capital World Investors
5.61%
Lynx1 Capital Advisors LLC
5.06%
Other
64.61%
股東類型
持股股東
佔比
Investment Advisor
34.01%
Hedge Fund
16.69%
Private Equity
14.32%
Corporation
10.60%
Investment Advisor/Hedge Fund
10.50%
Individual Investor
7.08%
Research Firm
5.09%
Venture Capital
0.83%
Bank and Trust
0.16%
Other
0.72%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
408
225.54M
103.12%
-7.62M
2025Q1
437
219.29M
100.27%
-22.18M
2024Q4
434
209.87M
100.10%
-25.68M
2024Q3
441
205.03M
101.51%
-25.11M
2024Q2
447
205.90M
102.27%
+9.93M
2024Q1
446
170.59M
100.21%
-14.52M
2023Q4
455
160.71M
95.67%
-29.40M
2023Q3
461
177.28M
107.46%
-30.31M
2023Q2
461
179.96M
123.50%
-2.72M
2023Q1
465
163.54M
112.33%
-14.45M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Pfizer Inc
22.03M
10.07%
--
--
Mar 31, 2025
TPG Capital, L.P.
18.72M
8.56%
--
--
Mar 31, 2025
Citadel Advisors LLC
10.20M
4.66%
+4.85M
+90.75%
Mar 31, 2025
Capital World Investors
12.27M
5.61%
+5.37M
+77.85%
Mar 31, 2025
Lynx1 Capital Advisors LLC
11.06M
5.06%
+182.29K
+1.68%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.81M
4.94%
-33.81K
-0.31%
Mar 31, 2025
Darwin Global Management Ltd
10.45M
4.78%
+10.45M
--
Mar 31, 2025
The Vanguard Group, Inc.
8.07M
3.69%
+91.07K
+1.14%
Mar 31, 2025
Belldegrun (Arie S)
7.56M
3.46%
-282.53K
-3.60%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.39M
3.38%
-16.37M
-68.89%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
WisdomTree BioRevolution Fund
0.78%
Virtus LifeSci Biotech Clinical Trials ETF
0.73%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Global X Genomics & Biotechnology ETF
0.2%
Zacks Small/Mid Cap ETF
0.14%
iShares Health Innovation Active ETF
0.04%
JPMorgan Fundamental Data Science Small Core ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
查看更多
WisdomTree BioRevolution Fund
佔比0.78%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.73%
Invesco NASDAQ Future Gen 200 ETF
佔比0.44%
Global X Genomics & Biotechnology ETF
佔比0.2%
Zacks Small/Mid Cap ETF
佔比0.14%
iShares Health Innovation Active ETF
佔比0.04%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
iShares Biotechnology ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
